Navigation Links
Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
Date:12/10/2007

t 333 days. At baseline, 63% of patients had evidence of bleeding (World Health Organization [WHO] Grade 1-4) and 44% had platelet counts less than or equal to 15,000/microliters. Seventeen patients had entered stage two of the study. Median platelet count was 143,500 microliters. Twenty-seven patients proceeded to long-term treatment with PROMACTA (maintenance stage), achieving median platelet counts of 104,000/microliters with only one patient (4%) showing evidence of bleeding (WHO Grade 2-4).

About PROMACTA

PROMACTA is an oral, non-peptide, thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets, and thus can be considered a platelet growth factor.(9) The efficacy and safety profile will be further examined in ongoing clinical trials. PROMACTA was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. It is being developed by GlaxoSmithKline.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit http://www.gsk.com.

Notes to Editors

PROMACTA(TM) is the registered trade mark of the GlaxoSmithKline group of companies.

PROMACTA(TM) is the proposed registered trademark to be used in the United States.

The study was financially supported by GlaxoSmithKline. Dr. Bussel is an Advisory Board Member for GlaxoSmithKline and has received research grant support, lecture fees, and consulting fees from GlaxoSmithKline and reports equity ownership in GlaxoSmithKline.

Enquiries

US Media inquiries:

Jeff McLaughlin 919-
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  The Pittsburgh Life Sciences Greenhouse (PLSG), the ... that one of its portfolio companies, Medrobotics Corporation, has ... Robotic System in the U.S.  ... Medrobotics," said John W. Manzetti , president and ... way since spinning out of The Robotics Institute at ...
(Date:8/4/2015)... , Aug. 4, 2015  Intec Pharma Ltd. (the ... company focused on developing drugs based on its proprietary ... its initial public offering in the United ... at a price to the public of $6.00 per ... the ordinary shares are being offered by the Company.  ...
(Date:8/4/2015)... 4, 2015 P&S Market ... overview, trends, DRO analysis, market segmentation, market size ... and top competitor profiles in: Global ... Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC on Global ...
Breaking Medicine Technology:Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... Calif., Oct. 11 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... analysis, it would stop enrollment in a Phase 2 ... patients with,recurrent, sensitive small cell lung cancer. The ... there would be,an adequate response rate to justify complete ...
... KineMed Inc., a,pathway-based drug discovery and development company, ... an investigational agent,to regenerate nerve cells in the ... and mood. The agent, part of a partnered ... behavioral test in a,preclinical model. The findings were ...
Cached Medicine Technology:Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 2Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 3KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3
(Date:8/4/2015)... ... 2015 , ... Worldwide Power Products acquires new assets, certifying ... in Texas. Effective July 1st of this year, Worldwide Power Products acquired operations ... the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 generators in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about ... Renew Man™ is standing up as a voice of authority for men seeking accurate ... aging industry with special experience and expertise in the safe and effective treatment of ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... “Dr. Google” before calling a physician. In an effort to share more and ... care provider in Pennsylvania to publicly share patient satisfaction ratings and comments about ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mesothelioma researchers in Australia have ... may be a viable option. Surviving Mesothelioma has just posted an article on ... surgeons at the University of New South Wales, peritoneal mesothelioma patients ...
(Date:8/4/2015)... Las Vegas, Nevada (PRWEB) , ... August 04, ... ... INTIMATELY FEMALE, a striking contemporary look at unique artistic expressions from a diverse ... Motel inside the Life Is Beautiful Music & Art Festival on September 25-27, ...
Breaking Medicine News(10 mins):Health News:North Texas Acquisition Press Release 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4
... Net Hospital,Alliance of Florida launched its new Web ... Alliance and links to its member hospitals, as,well ... the 2008,session, and news clips and editorials on ... is designed as a resource for the,public, legislators ...
... program helps Alzheimer,s and dementia patients and ... families regain ... More than 5.2 million Americans,including 250,000 Ohioans, struggle with ... being unveiled in the greater,Cleveland area offers new hope ...
... University, ... University, CENTER VALLEY, Pa., March 24 ... in healthcare,life science and consumer electronics products, today ... Program: Tom Byers, Ph.D. and Tina,Seelig, Ph.D., Stanford ...
... 24 Isolagen(TM), Inc.,(AMEX: ILE ) today announced the ... net. $5.85 million of the sale amount was,paid at the ... next six weeks., "This is an important development for ... facility will enable us to further pursue the,implementation of our ...
... not getting needed screenings for breast and cervical tumors , , ... 32 studies suggests that obese women -- particularly white women ... breast and cervical cancer. , No one knows why ... or Pap smears. And it,s not known why obesity seems ...
... Drugstore Ltd. (NYSE: NPD ) ("China Nepstar" or ... the number of,directly operated stores, today announced that the ... ordinary share of US$0.06 per share, based,on its net ... is payable on,or around May 12th, 2008, to shareholders ...
Cached Medicine News:Health News:Cleveland Area Homewatch CareGivers Unveil New Alzheimer's Program 2Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 2Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 3Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 4Health News:Isolagen, Inc. Sells Switzerland Facility 2Health News:Isolagen, Inc. Sells Switzerland Facility 3Health News:Obese Women Less Likely to Be Tested for Some Cancers 2Health News:China Nepstar Chain Drugstore Announces Dividend 2Health News:China Nepstar Chain Drugstore Announces Dividend 3
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... peptic ulcers are caused by H. pylori ... while the patient is still present with ... of waived or non-waived laboratories.,The Right Choice ... rapid H. pylori test available; helps to ...
... CHECK 02 PLUS CONCENTRATOR ANALYZER Now there ... the operating parameters necessary for performing concentrator ... ™, an efficient and cost-effective analyzer designed ... concentration (%), flow rate (L-min), and patient ...
... Exclusively for the Japanese market:, ... advanced, low-sound level, low-power-consumption, high-performance oxygen ... settings., ,Offered in an attractive, ... was specifically designed to meet the ...
Medicine Products: